Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc.

NEUP - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$12.28M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Neuphoria Therapeutics Inc.Neuphoria Therapeutics Inc.-0.4--55%--

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$12.28 Million
Enterprise Value$-7,547,458.00
Earnings per Share$-3.06
Beta0.77
Outstanding Shares5,411,334

Return

Return on Equity-54.68%ROE
Return on Assets-46.86%
Return on Invested Capital-39.67%

Valuation & Multiples

P/E Ratio-0.35P/E Ratio
PEG0.36PEG
Price to Sales-Price to Sales
Price to Book Ratio0.57Price to Book Ratio
Enterprise Value to Revenue-5.14
Enterprise Value to EBIT0.54
Enterprise Value to Net Income0
Total Debt to Enterprise-0.01
Debt to Equity0Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
September 18, 2026
EPS
-$0.13
Est. -$0.56
Revenue
$1.17 M
Reported

Institutional Put/Call Ratio

Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.

Put/Call Ratio0.00000%
Total Calls-
Total Puts-

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %11.08%▼ 25.77%
Total Invested$2.13M▼ 75.51%
Investors Holding10▼ 12.00%

About Bionomics Ltd.

1 employees
CEO: Spyridon Papapetropoulos

Neuphoria Therapeutics, Inc. is a biotechnology company currently advancing treatments through clinical trials. Its core mission involves pioneering therapies specifically engineered to address the intricate requirements of individuals l...